We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Hims & Hers Health, Inc. (HIMS) Stock Declines While Market Improves: Some Information for Investors
Read MoreHide Full Article
In the latest trading session, Hims & Hers Health, Inc. (HIMS - Free Report) closed at $41.98, marking a -34.63% move from the previous day. This move lagged the S&P 500's daily gain of 0.96%. Meanwhile, the Dow gained 0.89%, and the Nasdaq, a tech-heavy index, added 0.94%.
The company's stock has climbed by 17.13% in the past month, exceeding the Medical sector's loss of 0.85% and the S&P 500's gain of 0.5%.
The upcoming earnings release of Hims & Hers Health, Inc. will be of great interest to investors. On that day, Hims & Hers Health, Inc. is projected to report earnings of $0.17 per share, which would represent year-over-year growth of 183.33%. Simultaneously, our latest consensus estimate expects the revenue to be $551.84 million, showing a 74.83% escalation compared to the year-ago quarter.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $0.73 per share and revenue of $2.34 billion, indicating changes of +170.37% and +58.48%, respectively, compared to the previous year.
It's also important for investors to be aware of any recent modifications to analyst estimates for Hims & Hers Health, Inc. These recent revisions tend to reflect the evolving nature of short-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 0.59% higher. Hims & Hers Health, Inc. is currently a Zacks Rank #3 (Hold).
Valuation is also important, so investors should note that Hims & Hers Health, Inc. has a Forward P/E ratio of 88.32 right now. This represents a premium compared to its industry average Forward P/E of 32.25.
It is also worth noting that HIMS currently has a PEG ratio of 2.42. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. Medical Info Systems stocks are, on average, holding a PEG ratio of 2.94 based on yesterday's closing prices.
The Medical Info Systems industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 100, positioning it in the top 41% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Hims & Hers Health, Inc. (HIMS) Stock Declines While Market Improves: Some Information for Investors
In the latest trading session, Hims & Hers Health, Inc. (HIMS - Free Report) closed at $41.98, marking a -34.63% move from the previous day. This move lagged the S&P 500's daily gain of 0.96%. Meanwhile, the Dow gained 0.89%, and the Nasdaq, a tech-heavy index, added 0.94%.
The company's stock has climbed by 17.13% in the past month, exceeding the Medical sector's loss of 0.85% and the S&P 500's gain of 0.5%.
The upcoming earnings release of Hims & Hers Health, Inc. will be of great interest to investors. On that day, Hims & Hers Health, Inc. is projected to report earnings of $0.17 per share, which would represent year-over-year growth of 183.33%. Simultaneously, our latest consensus estimate expects the revenue to be $551.84 million, showing a 74.83% escalation compared to the year-ago quarter.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $0.73 per share and revenue of $2.34 billion, indicating changes of +170.37% and +58.48%, respectively, compared to the previous year.
It's also important for investors to be aware of any recent modifications to analyst estimates for Hims & Hers Health, Inc. These recent revisions tend to reflect the evolving nature of short-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 0.59% higher. Hims & Hers Health, Inc. is currently a Zacks Rank #3 (Hold).
Valuation is also important, so investors should note that Hims & Hers Health, Inc. has a Forward P/E ratio of 88.32 right now. This represents a premium compared to its industry average Forward P/E of 32.25.
It is also worth noting that HIMS currently has a PEG ratio of 2.42. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. Medical Info Systems stocks are, on average, holding a PEG ratio of 2.94 based on yesterday's closing prices.
The Medical Info Systems industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 100, positioning it in the top 41% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.